A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
Krebs, Matthew G Brunsvig, P Helland, A Segarra, NV Aix, SP Costa, EC Gomez, MD Perez, JMT Arriola, E Campelo, RG
Krebs, Matthew G
Brunsvig, P
Helland, A
Segarra, NV
Aix, SP
Costa, EC
Gomez, MD
Perez, JMT
Arriola, E
Campelo, RG
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Krebs MG, Brunsvig P, Helland A, Segarra N, Aix S, Costa E, et al. A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis. Journal for Immunotherapy of Cancer. 2019;7